The peroxisome proliferator-activated receptor-γ agonist rosiglitazone increases bone resorption in women with type 2 diabetes: A randomized, controlled trial

Ugis Gruntmanis, Steve Fordan, Hans K. Ghayee, Shuaib M Abdullah, Raphael See, Colby R. Ayers, Darren K McGuire

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

In previous studies, with up to 16 weeks of exposure to rosiglitazone or pioglitazone, circulating markers of bone formation [procollagen I N-terminal propeptide (P1NP), osteocalcin, and bone-specific alkaline phosphatase] decreased but no change in bone resorption markers was found. We examined the effect of rosiglitazone on bone resorption and formation markers when used for 24 weeks. This post-hoc analysis of a double-blind, placebo-controlled, randomized trial evaluated the effects of 6 months of rosiglitazone use versus placebo onc circulating markers of bone turnover in 111 patients with type 2 diabetes and cardiovascular disease or additional cardiac risk factors. The principal end points for analysis were changes in bone formation and resorption markers, measured by P1NP and carboxy-terminal cross-links (CTX), respectively. There were 111 subjects who completed the study and had baseline and 6-month data; mean age was 56, including 41% women and 67% nonwhite (50 black, 18 Hispanic, and six other), and subjects were evenly distributed between placebo and rosiglitazone groups. Women treated with rosiglitazone had higher CTX levels (0.43 ng/mL) than those who received placebo (0.23 ng/mL) (P = 0.007), with no significant differences in P1NP or OPG. Overall, in stratified analyses of men and in stratified analyses among different ethnicities, there were no statistically significant differences observed in CTX, P1NP, OPG, PTH, or 25-OHD between the treatment groups. Women taking rosiglitazone had higher circulating markers of bone resorption, which is contrary to prior studies of shorter duration, where the principal observation was a decrease in markers of bone formation.

Original languageEnglish (US)
Pages (from-to)343-349
Number of pages7
JournalCalcified Tissue International
Volume86
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

rosiglitazone
Peroxisome Proliferator-Activated Receptors
Bone Resorption
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Osteogenesis
Placebos
pioglitazone
Procollagen
Bone Remodeling
Osteocalcin
Hispanic Americans
Alkaline Phosphatase
Cardiovascular Diseases
Observation

Keywords

  • Bone formation and resorption
  • Carboxy-terminal cross-links
  • Diabetes
  • PPAR
  • Rosiglitazone

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The peroxisome proliferator-activated receptor-γ agonist rosiglitazone increases bone resorption in women with type 2 diabetes : A randomized, controlled trial. / Gruntmanis, Ugis; Fordan, Steve; Ghayee, Hans K.; Abdullah, Shuaib M; See, Raphael; Ayers, Colby R.; McGuire, Darren K.

In: Calcified Tissue International, Vol. 86, No. 5, 05.2010, p. 343-349.

Research output: Contribution to journalArticle

@article{9a05aa9ea5f84581877074147fafc25e,
title = "The peroxisome proliferator-activated receptor-γ agonist rosiglitazone increases bone resorption in women with type 2 diabetes: A randomized, controlled trial",
abstract = "In previous studies, with up to 16 weeks of exposure to rosiglitazone or pioglitazone, circulating markers of bone formation [procollagen I N-terminal propeptide (P1NP), osteocalcin, and bone-specific alkaline phosphatase] decreased but no change in bone resorption markers was found. We examined the effect of rosiglitazone on bone resorption and formation markers when used for 24 weeks. This post-hoc analysis of a double-blind, placebo-controlled, randomized trial evaluated the effects of 6 months of rosiglitazone use versus placebo onc circulating markers of bone turnover in 111 patients with type 2 diabetes and cardiovascular disease or additional cardiac risk factors. The principal end points for analysis were changes in bone formation and resorption markers, measured by P1NP and carboxy-terminal cross-links (CTX), respectively. There were 111 subjects who completed the study and had baseline and 6-month data; mean age was 56, including 41{\%} women and 67{\%} nonwhite (50 black, 18 Hispanic, and six other), and subjects were evenly distributed between placebo and rosiglitazone groups. Women treated with rosiglitazone had higher CTX levels (0.43 ng/mL) than those who received placebo (0.23 ng/mL) (P = 0.007), with no significant differences in P1NP or OPG. Overall, in stratified analyses of men and in stratified analyses among different ethnicities, there were no statistically significant differences observed in CTX, P1NP, OPG, PTH, or 25-OHD between the treatment groups. Women taking rosiglitazone had higher circulating markers of bone resorption, which is contrary to prior studies of shorter duration, where the principal observation was a decrease in markers of bone formation.",
keywords = "Bone formation and resorption, Carboxy-terminal cross-links, Diabetes, PPAR, Rosiglitazone",
author = "Ugis Gruntmanis and Steve Fordan and Ghayee, {Hans K.} and Abdullah, {Shuaib M} and Raphael See and Ayers, {Colby R.} and McGuire, {Darren K}",
year = "2010",
month = "5",
doi = "10.1007/s00223-010-9352-5",
language = "English (US)",
volume = "86",
pages = "343--349",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - The peroxisome proliferator-activated receptor-γ agonist rosiglitazone increases bone resorption in women with type 2 diabetes

T2 - A randomized, controlled trial

AU - Gruntmanis, Ugis

AU - Fordan, Steve

AU - Ghayee, Hans K.

AU - Abdullah, Shuaib M

AU - See, Raphael

AU - Ayers, Colby R.

AU - McGuire, Darren K

PY - 2010/5

Y1 - 2010/5

N2 - In previous studies, with up to 16 weeks of exposure to rosiglitazone or pioglitazone, circulating markers of bone formation [procollagen I N-terminal propeptide (P1NP), osteocalcin, and bone-specific alkaline phosphatase] decreased but no change in bone resorption markers was found. We examined the effect of rosiglitazone on bone resorption and formation markers when used for 24 weeks. This post-hoc analysis of a double-blind, placebo-controlled, randomized trial evaluated the effects of 6 months of rosiglitazone use versus placebo onc circulating markers of bone turnover in 111 patients with type 2 diabetes and cardiovascular disease or additional cardiac risk factors. The principal end points for analysis were changes in bone formation and resorption markers, measured by P1NP and carboxy-terminal cross-links (CTX), respectively. There were 111 subjects who completed the study and had baseline and 6-month data; mean age was 56, including 41% women and 67% nonwhite (50 black, 18 Hispanic, and six other), and subjects were evenly distributed between placebo and rosiglitazone groups. Women treated with rosiglitazone had higher CTX levels (0.43 ng/mL) than those who received placebo (0.23 ng/mL) (P = 0.007), with no significant differences in P1NP or OPG. Overall, in stratified analyses of men and in stratified analyses among different ethnicities, there were no statistically significant differences observed in CTX, P1NP, OPG, PTH, or 25-OHD between the treatment groups. Women taking rosiglitazone had higher circulating markers of bone resorption, which is contrary to prior studies of shorter duration, where the principal observation was a decrease in markers of bone formation.

AB - In previous studies, with up to 16 weeks of exposure to rosiglitazone or pioglitazone, circulating markers of bone formation [procollagen I N-terminal propeptide (P1NP), osteocalcin, and bone-specific alkaline phosphatase] decreased but no change in bone resorption markers was found. We examined the effect of rosiglitazone on bone resorption and formation markers when used for 24 weeks. This post-hoc analysis of a double-blind, placebo-controlled, randomized trial evaluated the effects of 6 months of rosiglitazone use versus placebo onc circulating markers of bone turnover in 111 patients with type 2 diabetes and cardiovascular disease or additional cardiac risk factors. The principal end points for analysis were changes in bone formation and resorption markers, measured by P1NP and carboxy-terminal cross-links (CTX), respectively. There were 111 subjects who completed the study and had baseline and 6-month data; mean age was 56, including 41% women and 67% nonwhite (50 black, 18 Hispanic, and six other), and subjects were evenly distributed between placebo and rosiglitazone groups. Women treated with rosiglitazone had higher CTX levels (0.43 ng/mL) than those who received placebo (0.23 ng/mL) (P = 0.007), with no significant differences in P1NP or OPG. Overall, in stratified analyses of men and in stratified analyses among different ethnicities, there were no statistically significant differences observed in CTX, P1NP, OPG, PTH, or 25-OHD between the treatment groups. Women taking rosiglitazone had higher circulating markers of bone resorption, which is contrary to prior studies of shorter duration, where the principal observation was a decrease in markers of bone formation.

KW - Bone formation and resorption

KW - Carboxy-terminal cross-links

KW - Diabetes

KW - PPAR

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=77953356133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953356133&partnerID=8YFLogxK

U2 - 10.1007/s00223-010-9352-5

DO - 10.1007/s00223-010-9352-5

M3 - Article

C2 - 20354684

AN - SCOPUS:77953356133

VL - 86

SP - 343

EP - 349

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 5

ER -